Unlike Theranos, Truvian is seeking regulatory clearance from the outset, and bringing in laboratory experts to validate its approach. As it approaches its FDA submission, Truvian plans to ramp up clinical trials and manufacturing of cartridges for its device.
Category: MedCityNews
In a Q&A, Truvian Sciences CEO Jeff Hawkins and Dena Marrinucci, founder and SVP Corporate Development and Business Operations talk about their point-of care blood testing technology.
Truvian Sciences is developing an automated benchtop broad panel testing system on a “small sample of blood” to support which the company just raised $27.1 million